U.S. naloxone market growth is driven by ongoing opioid crisis. Naloxone is an opioid antagonist that is used for the complete or partial reversal of opioid overdose, including reversal of respiratory depression, sedation, and hypotension. It works by blocking or reversing the effects of opioids by binding to the opioid receptors. With the exponential rise in opioid overdoses and deaths involving prescription pain medications and heroin in the U.S., naloxone play an important role in reducing mortality caused by opioid overdose events. Its wide availability in both pharmacy and non-prescription settings has improved accessibility. The CDC recommends co-prescribing of Naloxone with prescription opioids in high-risk cases to prevent overdose deaths.

Market Dynamics:

U.S. naloxone market  growth is driven by growing opioid epidemic w that results in a large number of opioid overdose deaths over the past few decades. Increasing prevalence of prescription pain reliever and heroin abuse also drives the market growth. However, pricing pressures and lower brand name drug revenues amid generic competition can hamper the market growth.  Higher accessibility of Naloxone formulations like intranasal spray and auto-injectors as well as collaborations to expand access can offer significant growth opportunities. Initiatives by state and federal agencies to promote naloxone co-prescription and wider distribution through community programs can also drive the market growth.

 Key Features of the Study:

- This report provides in-depth analysis of the U.S. naloxone market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year

- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

- It profiles key players in the U.S. naloxone market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

- Key companies covered as a part of this study include Adapt Pharma Inc., Mylan N.V., Hospira Inc. (Pfizer Inc.), Kaleo Inc., Amphastar Pharmaceuticals Inc., Emergent BioSolutions Inc., Indivior PLC, Akorn, Inc., Hikma Pharmaceuticals PLC, Viatris Inc., Sandoz (a Novartis division), Teva Pharmaceuticals, Amneal Pharmaceuticals, Somerset Pharma, LLC, Orexo AB, UCB Pharma, West Ward Pharmaceuticals, Purdue Pharma.

- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

- U.S. naloxone market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. naloxone market

Detailed Segmentation-

• By Drug Type
• • Branded
  • Generic
• By Route of Administration
  
  • Intranasal Administration
  • Intramuscular Administration
  • Intravenous Administration
  • others
• By Distribution Channel
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Company Profiles:
  • Adapt Pharma Inc.
  • Mylan N.V.
  • Hospira Inc. (Pfizer Inc.)
  • Kaleo Inc.
  • Amphastar Pharmaceuticals Inc.
  • Emergent BioSolutions Inc.
  • Indivior PLC
  • Akorn, Inc.
  • Hikma Pharmaceuticals PLC
  • Viatris Inc.
  • Sandoz (a Novartis division)
  • Teva Pharmaceuticals
  • Amneal Pharmaceuticals
  • Somerset Pharma, LLC
  • Orexo AB
  • UCB Pharma
  • West Ward Pharmaceuticals
  • Purdue Pharma